Scinai Immunotherapeutics Strives for Nasdaq Compliance
Company Announcements

Scinai Immunotherapeutics Strives for Nasdaq Compliance

Scinai Immunotherapeutics (SCNI) has released an update.

Scinai Immunotherapeutics, a biotech company, has been granted an extension by the Nasdaq Hearings Panel to regain compliance with stockholders’ equity requirements for continued listing on the Nasdaq Capital Market. The firm has until August 14, 2024, to demonstrate compliance, following its presentation of a plan to convert a significant loan into equity. While the company has been given the opportunity to address the equity deficiency and maintain its listing, there is no guarantee of meeting the conditions or achieving compliance.

For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics to Hold Annual Shareholder Meeting
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics Licenses Global Rights
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics Restructures Debt, Eyes Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App